BRAF and neoplasm: Previous experimental work has shown that drug combinations, drug doses and treatment schedules all impact the evolution of drug-resistant tumour subclones in melanoma when the tumours are subjected to inhibitors that target the BRAF-MEK-ERK pathway [4, 52].